1-methylethyl 2-[{(3S)-1-[(5-ethyl-2-thienyl)methyl]-3-pyrrolidinyl}(methyl)amino]-3-pyridinecarboxylate | 1315558-22-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃
• 英文名称: 1-methylethyl 2-[{(3S)-1-[(5-ethyl-2-thienyl)methyl]-3-pyrrolidinyl}(methyl)amino]-3-pyridinecarboxylate
• 英文别名: propan-2-yl 2-[[(3S)-1-[(5-ethylthiophen-2-yl)methyl]pyrrolidin-3-yl]-methylamino]pyridine-3-carboxylate
• CAS: 1315558-22-5
• 化学式: C₂₁H₂₉N₃O₂S
• 分子量: 387.546
• InChiKey: MVHSUVJQKRMKGY-INIZCTEOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  27
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  73.9
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• [EN] VOLTAGE-GATED SODIUM CHANNEL BLOCKERS<br/>[FR] BLOQUEURS DES CANAUX SODIQUES VOLTAGE-DÉPENDANTS
  申请人：GLAXO GROUP LTD

  公开号：WO2013006596A1

  公开（公告）日：2013-01-10

  In general, the present invention relates to uses of voltage-gated sodium channel blocker compounds,, which include corresponding precursors, intermediates, monomers and dimers, corresponding pharmaceutical compositions, compound preparation and treatment methods for respiratory and respiratory tract diseases. In particular, the present invention also relates to methods and uses for treatment of respiratory or respiratory tract diseases, which comprises administering to a subject in need thereof an effective amount of a compound of the present invention.

  一般而言，本发明涉及使用电压门控钠通道阻滞剂化合物，包括相应的前体、中间体、单体和二聚体，相应的药物组合物，化合物制备和治疗方法，用于呼吸和呼吸道疾病。具体而言，本发明还涉及用于治疗呼吸或呼吸道疾病的方法和用途，包括向需要的受试者施用本发明化合物的有效量。
• VOLTAGE-GATED SODIUM CHANNEL BLOCKERS
  申请人：Boehm Jeffrey Charles

  公开号：US20130023541A1

  公开（公告）日：2013-01-24

  The present invention relates to voltage-gated sodium channel blocker intermediates, compounds and dimers, corresponding pharmaceutical compositions, compound preparation and treatment methods for respiratory or respiratory tract diseases.

  本发明涉及电压门控钠通道阻滞剂中间体、化合物和二聚体，相应的药物组合物、化合物制备和治疗呼吸或呼吸道疾病的方法。
• [EN] VOLTAGE-GATED SODIUM CHANNEL BLOCKERS<br/>[FR] BLOQUEURS DE CANAUX SODIQUES SENSIBLES AU POTENTIEL
  申请人：GLAXO GROUP LTD

  公开号：WO2011088201A1

  公开（公告）日：2011-07-21

  The present invention relates to voltage-gated sodium channel blocker intermediates, compounds and dimers, corresponding pharmaceutical compositions, compound preparation and treatment methods for respiratory or respiratory tract diseases.